

Endologix Investor Relations Department 2 Musick Irvine, CA 92618 United States

Visit IR website ☐ Sign-up for Email alerts ☐

4.57
4:00 PM ET Apr 19, 2018
0.26 🕇 (+6.032%)
4.28 - 4.64
3.75 - 7.66
457,243

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

Addressing a signi... (more)

Stock Performance



Press Releases [View all]

Apr 3, 2018

Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018

Mar 19, 2018

Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems

Mar 5. 2018

Endologix, Inc. Announces Enrollment of the First Patient in EVAS2 IDE Clinical Study of the Nellix® EndoVascular Aneurysm Sealing System

Feb 21, 2018

John McDermott Steps Down as Chief Executive Officer of Endologix, Inc.

Feb 21, 2018

Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results

Upcoming Events [View all]

Apr 24-27, 2018

Endologix Events at Charing Cross Symposium

May 2, 2018 4:30 PM ET

Endologix 2018 First Quarter Financial Results Conference Call

Financials [View all]

Third Quarter Financial Results

Mar 13, 2018

Annual Report (10-K)

Apr 17, 2018

Proxy Statement (DEF 14A)

Nov 7, 2017

Quarterly Report (10-Q)

Aug 4, 2017

Quarterly Report (10-Q)

May 5, 2017

Quarterly Report (10-Q)